The Mass Effect

March 11, 2011 is a day I will never forget. I had just arrived home to my Tokyo apartment and was searching the house for some documents I needed for an urgent errand. As I leafed through stacks of papers on my desk, I began feeling the all-too-common motion of an earthquake. Having lived in Tokyo for five years, the sensation had become commonplace in my mind, and I continued looking around. At first, I assumed it was just like all the other minor quakes I had experienced in the past.

[1]  W. Weber,et al.  First Clinical Evidence That Imaging with Somatostatin Receptor Antagonists Is Feasible , 2011, The Journal of Nuclear Medicine.

[2]  T. Visser,et al.  Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  T. Visser,et al.  Tumour uptake of the radiolabelled somatostatin analogue [DOTA0,TYR3]octreotide is dependent on the peptide amount , 1999, European Journal of Nuclear Medicine.

[5]  G Sgouros,et al.  Bone marrow dosimetry for radioimmunotherapy: theoretical considerations. , 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[6]  Wolfgang A Weber,et al.  PET of Somatostatin Receptor–Positive Tumors Using 64Cu- and 68Ga-Somatostatin Antagonists: The Chelate Makes the Difference , 2011, The Journal of Nuclear Medicine.

[7]  Judit Erchegyi,et al.  Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors , 2006, Proceedings of the National Academy of Sciences.

[8]  M. Bergström,et al.  In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass. , 2010, Nuclear medicine and biology.

[9]  E. Krenning,et al.  Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Matthias Briel,et al.  Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  M G Stabin,et al.  Absorbed fractions for electrons and beta particles in spheres of various sizes. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.